China Professional Acne Medication Market by Acne Type (Inflammatory Acne and Non-inflammatory Acne), by Formulation (Topical Medications and Oral Medications), by Therapeutic Class (Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide, and Others), and by Distribution Channel (Med Spa, Aesthetician, Dermatologist, and Other Professional Channels) – Opportunity Analysis and Industry Forecast, 2024–2030

China Professional Acne Medication Market

Industry:  Consumer Goods | Publish Date: Feb 2024 | No of Pages:  110 | No. Tables:  77 | No. Figures:  42

Market Definition

China Professional Acne Medication Market was valued at USD 362.53 million in 2023 and is predicted to reach USD 653.41 million by 2030, with a CAGR of 8.7% from 2024 to 2030. The professional acne medicine market refers to dermatologist-prescribed specialist skincare formulations that manage both inflammatory and non-inflammatory lesions while avoiding scarring. These formulations provide benefits such as powerful and customized components, which typically outperform over-the-counter alternatives.

Professional acne treatments, which are widely used in dermatological services, cater to those who have severe or persistent acne problems, assuring a better degree of efficacy and control. As the demand for advanced skincare grows, this market will continue to play an important role in delivering tailored and medically guided ways to cleaner and healthier skin.

Utilisation of Advanced Dermatological Technologies Fuelling Growth of the Market

Technological Innovations are a paramount driver of the flourishing professional acne medication market in China. Presence of dermatological technologies, notably in laser therapies and microdermabrasion, have brought about a revolution in acne treatment options. These cutting-edge treatments provide patients with more effective and minimally invasive solutions for managing acne-related skin issues. According to the Chinese Medical Association Publishing House, recent developments in artificial intelligence (AI) and skin imaging technology, exemplified by the Chinese Skin Image Database (CSID), have significantly improved dermatological AI applications. This enhanced precision and individualization of treatment options have fuelled patient trust and satisfaction, subsequently driving the robust growth of the industry.

 

Evolving Lifestyles Towards Urbanisation Drives the Growth of Market

Changing Lifestyles which include transformations in daily routines, higher exposure to pollution, and heightened stress levels are central drivers behind the expanding professional acne medication market in China. These evolving lifestyle factors have led to a surge in acne cases, elevating the demand for professional acne treatments. As lifestyles evolve with increasing urbanization and fast-paced daily routines, individuals are exposed to higher levels of pollution and experience elevated stress. This rising demand fuelled the growth of the professional acne medication market as individuals seek effective solutions to maintain clear and healthy skin in the face of changing environmental and lifestyle factors.

 

Regulatory Challenges Restricts Market Expansion 

The stringent regulations and compliance standards in China's healthcare sector present formidable obstacles to the growth of the professional acne medication market. Navigating the intricate regulatory landscape can be a challenging and time-consuming process for both domestic and foreign market participants. 

Expanding Healthcare Access Fuels Future Growth of the Market

The growing accessibility to healthcare services and extended insurance coverage presents a promising opportunity for the future growth of China's professional acne medication market. As more individuals gain access to healthcare facilities and acquire insurance coverage that encompasses professional acne treatments, the market can anticipate a surge in demand. This expanded accessibility allows a broader demographic to seek specialized dermatological care, fostering the market's expansion by accommodating a more extensive patient base. As a result, this increased accessibility and affordability creates an optimistic outlook for the market's future growth within China.

 

Competitive Landscape

China professional acne medication market includes several market players such as Bayer AG, Nestle S.A., Pfizer Inc., Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Galderma S.A., Allergan plc, Stiefel Laboratories Inc., Bausch Health Companies Inc. and others.

China Professional Acne Medication Market Key Segments

By Acne Type    

  • Inflammatory Acne 

  • Non-inflammatory Acne 

By Formulation    

  • Topical Medications

  • Oral Medications 

By Therapeutic Class

  • Retinoids

  • Antibiotics

  • Salicylic Acid

  • Benzoyl Peroxide

  • Others

By Distribution Channel

  • Med Spa

  • Aesthetician

  • Dermatologist

  • Other Professional Channels

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2023

USD 362.53 Million

Revenue Forecast in 2030

USD 653.41 Million

Growth Rate

CAGR of 8.7% from 2024 to 2030

Analysis Period

2023–2030

Base Year Considered

2023

Forecast Period

2024–2030

Market Size Estimation

Million (USD)

Growth Factors

Utilisation of Advanced dermatological technologies

Evolving lifestyle towards urbanization

 Key Market Players

10

Market Share

Available for 10 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

Test

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2      CHINA PROFESSIONAL ACNE MEDICATION MARKET – EXECUTIVE SUMMARY

           2.1.      MARKET SNAPSHOT, 2023 - 2030, MILLION USD

3      PORTER’S FIVE FORCE MODEL ANALYSIS

           3.1      BARGAINING POWER OF SUPPLIERS

           3.2      BARGAINING POWER OF BUYERS

           3.3      DEGREE OF COMPETITION

           3.4      THREAT OF SUBSTITUTE

           3.5      THREAT OF NEW ENTRANTS

4      MARKET SHARE ANALYSIS

           4.1      MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

5      MARKET DYNAMICS

           5.1      GROWTH DRIVERS

                         5.1.1      DRIVER 1

                         5.1.2      DRIVER 2

                         5.1.3      DRIVER 3

                         5.1.4      DRIVER 4

           5.2      CHALLENGES

                         5.2.1      CHALLENGE 1

                         5.2.2      CHALLENGE 2

                         5.2.3      CHALLENGE 3

                         5.2.4      CHALLENGE 4

           5.3      OPPORTUNITIES

                         5.3.1      OPPORTUNITY 1

                         5.3.2      OPPORTUNITY 2

6       CHINA PROFESSIONAL ACNE MEDICATION MARKET BY ACNE TYPE

           6.1      OVERVIEW

           6.2      INFLAMMATORY ACNE MARKET

           6.3      NON-INFLAMMATORY ACNE MARKET

7       CHINA PROFESSIONAL ACNE MEDICATION MARKET BY FORMULATION

           7.1      OVERVIEW

           7.2      TOPICAL MEDICATIONS MARKET

           7.3      ORAL MEDICATIONS MARKET

8       CHINA PROFESSIONAL ACNE MEDICATION MARKET BY THERAPEUTIC CLASS

           8.1      OVERVIEW

           8.2      RETINOIDS MARKET

           8.3      ANTIBIOTICS MARKET

           8.4      SALICYLIC ACID MARKET

           8.5      BENZOYL PEROXIDE MARKET

           8.6      OTHERS MARKET

9       CHINA PROFESSIONAL ACNE MEDICATION MARKET BY DISTRIBUTION CHANNEL

           9.1      OVERVIEW

           9.2      MED SPA MARKET

           9.3      AESTHETICIAN MARKET

           9.4      DERMATOLOGIST MARKET

           9.5      OTHER PROFESSIONAL CHANNELS MARKET

10   COMPANY PROFILES

           10.1   ALMIRALL S.A.

                         10.1.1   COMPANY OVERVIEW

                         10.1.2   COMPANY SNAPSHOT

                         10.1.3   OPERATING BUSINESS SEGMENTS

                         10.1.4   PRODUCT PORTFOLIO

                         10.1.5   BUSINESS PERFORMANCE

                         10.1.6   BUSINESS SEGMENTS

                         10.1.7   GEOGRAPHIC SEGMENTS

                         10.1.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.1.9   PRIMARY MARKET COMPETITORS

           10.2   BAUSCH HEALTH COMPANIES, INC.

                         10.2.1   COMPANY OVERVIEW

                         10.2.2   COMPANY SNAPSHOT

                         10.2.3   OPERATING BUSINESS SEGMENTS

                         10.2.4   PRODUCT PORTFOLIO

                         10.2.5   BUSINESS PERFORMANCE

                         10.2.6   BUSINESS SEGMENTS

                         10.2.7   GEOGRAPHIC SEGMENTS

                         10.2.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.2.9   PRIMARY MARKET COMPETITORS

           10.3   GLAXOSMITHKLINE PLC (GSK)

                         10.3.1   COMPANY OVERVIEW

                         10.3.2   COMPANY SNAPSHOT

                         10.3.3   OPERATING BUSINESS SEGMENTS

                         10.3.4   PRODUCT PORTFOLIO

                         10.3.5   BUSINESS PERFORMANCE

                         10.3.6   BUSINESS SEGMENTS

                         10.3.7   GEOGRAPHIC SEGMENTS

                         10.3.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.3.9   PRIMARY MARKET COMPETITORS

           10.4   GALDERMA S.A.

                         10.4.1   COMPANY OVERVIEW

                         10.4.2   COMPANY SNAPSHOT

                         10.4.3   OPERATING BUSINESS SEGMENTS

                         10.4.4   PRODUCT PORTFOLIO

                         10.4.5   BUSINESS PERFORMANCE

                         10.4.6   BUSINESS SEGMENTS

                         10.4.7   GEOGRAPHIC SEGMENTS

                         10.4.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.4.9   PRIMARY MARKET COMPETITORS

           10.5   SUN PHARMACEUTICAL INDUSTRIES LIMITED

                         10.5.1   COMPANY OVERVIEW

                         10.5.2   COMPANY SNAPSHOT

                         10.5.3   OPERATING BUSINESS SEGMENTS

                         10.5.4   PRODUCT PORTFOLIO

                         10.5.5   BUSINESS PERFORMANCE

                         10.5.6   BUSINESS SEGMENTS

                         10.5.7   GEOGRAPHIC SEGMENTS

                         10.5.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.5.9   PRIMARY MARKET COMPETITORS

           10.6   TEVA PHARMACEUTICAL INDUSTRIES LTD.

                         10.6.1   COMPANY OVERVIEW

                         10.6.2   COMPANY SNAPSHOT

                         10.6.3   OPERATING BUSINESS SEGMENTS

                         10.6.4   PRODUCT PORTFOLIO

                         10.6.5   BUSINESS PERFORMANCE

                         10.6.6   BUSINESS SEGMENTS

                         10.6.7   GEOGRAPHIC SEGMENTS

                         10.6.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.6.9   PRIMARY MARKET COMPETITORS

           10.7   JOHNSON AND JOHNSON

                         10.7.1   COMPANY OVERVIEW

                         10.7.2   COMPANY SNAPSHOT

                         10.7.3   OPERATING BUSINESS SEGMENTS

                         10.7.4   PRODUCT PORTFOLIO

                         10.7.5   BUSINESS PERFORMANCE

                         10.7.6   BUSINESS SEGMENTS

                         10.7.7   GEOGRAPHIC SEGMENTS

                         10.7.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.7.9   PRIMARY MARKET COMPETITORS

           10.8   ELI LILLY AND COMPANY

                         10.8.1   COMPANY OVERVIEW

                         10.8.2   COMPANY SNAPSHOT

                         10.8.3   OPERATING BUSINESS SEGMENTS

                         10.8.4   PRODUCT PORTFOLIO

                         10.8.5   BUSINESS PERFORMANCE

                         10.8.6   BUSINESS SEGMENTS

                         10.8.7   GEOGRAPHIC SEGMENTS

                         10.8.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.8.9   PRIMARY MARKET COMPETITORS

           10.9   MYLAN N.V.

                         10.9.1   COMPANY OVERVIEW

                         10.9.2   COMPANY SNAPSHOT

                         10.9.3   OPERATING BUSINESS SEGMENTS

                         10.9.4   PRODUCT PORTFOLIO

                         10.9.5   BUSINESS PERFORMANCE

                         10.9.6   BUSINESS SEGMENTS

                         10.9.7   GEOGRAPHIC SEGMENTS

                         10.9.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.9.9   PRIMARY MARKET COMPETITORS

           10.10   DAIICHI SANKYO COMPANY, LTD

                         10.10.1   COMPANY OVERVIEW

                         10.10.2   COMPANY SNAPSHOT

                         10.10.3   OPERATING BUSINESS SEGMENTS

                         10.10.4   PRODUCT PORTFOLIO

                         10.10.5   BUSINESS PERFORMANCE

                         10.10.6   BUSINESS SEGMENTS

                         10.10.7   GEOGRAPHIC SEGMENTS

                         10.10.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.10.9   PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. CHINA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 2. INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 3. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 4. CHINA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 5. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 6. ORAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 7. CHINA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 8. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 9. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 10. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 11. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 12. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 13. CHINA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 14. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 15. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 16. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 17. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 18. BAYER AG: COMPANY SNAPSHOT

TABLE 19. BAYER AG: OPERATING BUSINESS SEGMENTS

TABLE 20. BAYER AG: PRODUCT PORTFOLIO

TABLE 21. BAYER AG: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 22. BAYER AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 23. BAYER AG: KEY STRATERGY

TABLE 24. NESTLE S.A.: COMPANY SNAPSHOT

TABLE 25. NESTLE S.A.: OPERATING BUSINESS SEGMENTS

TABLE 26. NESTLE S.A.: PRODUCT PORTFOLIO

TABLE 27. NESTLE S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 28. NESTLE S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 29. NESTLE S.A.: KEY STRATERGY

TABLE 30. PFIZER INC.: COMPANY SNAPSHOT

TABLE 31. PFIZER INC.: OPERATING BUSINESS SEGMENTS

TABLE 32. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 33. PFIZER INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 34. PFIZER INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 35. PFIZER INC.: KEY STRATERGY

TABLE 36. JOHNSON AND JOHNSON: COMPANY SNAPSHOT

TABLE 37. JOHNSON AND JOHNSON: OPERATING BUSINESS SEGMENTS

TABLE 38. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO

TABLE 39. JOHNSON AND JOHNSON: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 40. JOHNSON AND JOHNSON: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 41. JOHNSON AND JOHNSON: KEY STRATERGY

TABLE 42. ROCHE HOLDING AG: COMPANY SNAPSHOT

TABLE 43. ROCHE HOLDING AG: OPERATING BUSINESS SEGMENTS

TABLE 44. ROCHE HOLDING AG: PRODUCT PORTFOLIO

TABLE 45. ROCHE HOLDING AG: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 46. ROCHE HOLDING AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 47. ROCHE HOLDING AG: KEY STRATERGY

TABLE 48. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT

TABLE 49. GLAXOSMITHKLINE PLC: OPERATING BUSINESS SEGMENTS

TABLE 50. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 51. GLAXOSMITHKLINE PLC: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 52. GLAXOSMITHKLINE PLC: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 53. GLAXOSMITHKLINE PLC: KEY STRATERGY

TABLE 54. GALDERMA S.A.: COMPANY SNAPSHOT

TABLE 55. GALDERMA S.A.: OPERATING BUSINESS SEGMENTS

TABLE 56. GALDERMA S.A.: PRODUCT PORTFOLIO

TABLE 57. GALDERMA S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 58. GALDERMA S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 59. GALDERMA S.A.: KEY STRATERGY

TABLE 60. ALLERGAN PLC: COMPANY SNAPSHOT

TABLE 61. ALLERGAN PLC: OPERATING BUSINESS SEGMENTS

TABLE 62. ALLERGAN PLC: PRODUCT PORTFOLIO

TABLE 63. ALLERGAN PLC: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 64. ALLERGAN PLC: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 65. ALLERGAN PLC: KEY STRATERGY

TABLE 66. STIEFEL LABORATORIES INC.: COMPANY SNAPSHOT

TABLE 67. STIEFEL LABORATORIES INC.: OPERATING BUSINESS SEGMENTS

TABLE 68. STIEFEL LABORATORIES INC.: PRODUCT PORTFOLIO

TABLE 69. STIEFEL LABORATORIES INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 70. STIEFEL LABORATORIES INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 71. STIEFEL LABORATORIES INC.: KEY STRATERGY

TABLE 72. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT

TABLE 73. BAUSCH HEALTH COMPANIES INC.: OPERATING BUSINESS SEGMENTS

TABLE 74. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO

TABLE 75. BAUSCH HEALTH COMPANIES INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 76. BAUSCH HEALTH COMPANIES INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 77. BAUSCH HEALTH COMPANIES INC.: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. BARGAINING POWER OF SUPPLIERS

FIGURE 2. BARGAINING POWER OF BUYERS

FIGURE 3. DEGREE OF COMPETITION

FIGURE 4. THREAT OF SUBSTITUTE

FIGURE 5. THREAT OF NEW ENTRANTS

FIGURE 6. CHINA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

FIGURE 7. INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 8. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 9. CHINA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

FIGURE 10. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 11. ORAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 12. CHINA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

FIGURE 13. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 14. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 15. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 16. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 17. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 18. CHINA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

FIGURE 19. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 20. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 21. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 22. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 23. BAYER AG: NET SALES, (2021-2023)

FIGURE 24. BAYER AG: PRIMARY MARKET COMPETITORS

FIGURE 25. NESTLE S.A.: NET SALES, (2021-2023)

FIGURE 26. NESTLE S.A.: PRIMARY MARKET COMPETITORS

FIGURE 27. PFIZER INC.: NET SALES, (2021-2023)

FIGURE 28. PFIZER INC.: PRIMARY MARKET COMPETITORS

FIGURE 29. JOHNSON AND JOHNSON: NET SALES, (2021-2023)

FIGURE 30. JOHNSON AND JOHNSON: PRIMARY MARKET COMPETITORS

FIGURE 31. ROCHE HOLDING AG: NET SALES, (2021-2023)

FIGURE 32. ROCHE HOLDING AG: PRIMARY MARKET COMPETITORS

FIGURE 33. GLAXOSMITHKLINE PLC: NET SALES, (2021-2023)

FIGURE 34. GLAXOSMITHKLINE PLC: PRIMARY MARKET COMPETITORS

FIGURE 35. GALDERMA S.A.: NET SALES, (2021-2023)

FIGURE 36. GALDERMA S.A.: PRIMARY MARKET COMPETITORS

FIGURE 37. ALLERGAN PLC: NET SALES, (2021-2023)

FIGURE 38. ALLERGAN PLC: PRIMARY MARKET COMPETITORS

FIGURE 39. STIEFEL LABORATORIES INC.: NET SALES, (2021-2023)

FIGURE 40. STIEFEL LABORATORIES INC.: PRIMARY MARKET COMPETITORS

FIGURE 41. BAUSCH HEALTH COMPANIES INC.: NET SALES, (2021-2023)

FIGURE 42. BAUSCH HEALTH COMPANIES INC.: PRIMARY MARKET COMPETITOR

KEY PLAYERS

  • Bayer AG

  • Nestle S.A.

  • Pfizer Inc.

  • Johnson & Johnson

  • Roche Holding AG

  • GlaxoSmithKline plc

  • Galderma S.A.

  • Allergan plc

  • Stiefel Laboratories Inc.

  • Bausch Health Companies Inc.


Frequently Asked Questions
What will be the worth of the China professional acne medication market by the end of 2030?

According to the report published by Next Move Consulting, the China professional acne medication market business is expected to hit at USD 653.41 million by 2030.

What are the leading companies in the China professional acne medication market?

The China professional acne medication industry includes several market players such as Bayer AG, Nestle S.A., Pfizer Inc., Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Galderma S.A., Allergan plc, Stiefel Laboratories Inc., Bausch Health Companies Inc. and others.

What are the market segmentations and scope of the study for the China professional acne medication industry?

China professional acne medication market share is segmented based on acne type, formulation, therapeutic class, distribution channel, and geography.

What are the factors that are driving the growth of the professional acne medication market in China?

The factors driving the growth of the professional acne medication market in China include technological innovations and changing lifestyles.

What is restraining the growth of the China professional acne medication market?

The stringent regulations and compliance standards in China's healthcare sector pose a significant challenge to its expansion.